Navigation Links
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
Date:7/10/2009

VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Center and the Center for Human Immunology, NERD (New Research and Development) Seminar Series, which will take place on Friday July 10, 2009 at the NIH's Clinical Center located at the main NIH campus, on 9000 Rockville Pike, Bethesda, MD. The title of Dr. Talor's presentation is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work".

In the presentation, Dr. Talor will discuss Multikine's immunotherapy clinical program for cancer, the unique mechanism of action of Multikine (published in the Journal of Clinical Oncology) and the way Multikine imparts the patient's own immune response with the ability to mount a robust anti-tumor immune response against his/her tumor. Dr. Talor will also discuss the clinical findings from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians and researchers in the field as a key to improving disease outcome in these patients.

Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current Material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH collaborative study will use samples collected from patients with a
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Posts New Corporate Presentation to Website
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
5. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
6. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
7. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
8. CEL-SCI Corporation Reports First Quarter Financial Results
9. CEL-SCI Corporation Announces 2007 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... April 14, 2011 Attorney General Roy Cooper warned ... that a measure giving immunity to pharmaceutical companies could ... "hundreds of millions of dollars." Still, the ... controversial measure.  HB 542 could go to the House ...
... ANN ARBOR, Mich., April 14, 2011 Adeona Pharmaceuticals, ... innovative medicines for serious central nervous system diseases, announced ... to discuss the results from the clinical study evaluating ... disease and mild cognitive impairment on Friday, April 15, ...
Cached Medicine Technology:GOP's Big Pharma Protection to Cost NC Taxpayers "Hundreds of Millions" 2Adeona to Host Conference Call 2
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... research into diseases and treatments, experts say , FRIDAY, ... first detailed map of the human epigenome, gaining greater ... the past, we,ve been limited to viewing small snippets ... the Genomic Analysis Laboratory at the Salk Institute for ...
... physicians will be using electronic prescribing and other health ... million federal grant secured by U.S. Senator Patrick Leahy. ... Technology Leaders, Inc. (VITL), will provide incentives to physicians ... In June, Vermont was cited by Surescripts as the ...
... Avon Foundation for Women is marking Breast Cancer Awareness ... tributes. Throughout October, the Foundation will call attention to ... and raise millions of dollars for the breast cancer ... of fundraising products, Avon Walks for Breast Cancer, and ...
... founding a new publication, the Critical Ultrasound ... as the official publication of WINFOCUS (World Interactive ... will be published in October 2009. ... for clinicians and health professionals using point-of-care ultrasound ...
... ... ... -- While most Canadians have brushed aside worries about H1N1, officials say that the ... West is keeping its students up-to-date with current information about the disease and preventative ...
... off disease and decline, study finds, , FRIDAY, Oct. ... retirement may be surprising: work. , Retirees who continue ... likely to experience physical decline and disease, new U.S. ... and Retirement Study, researchers analyzed six years of information ...
Cached Medicine News:Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 2Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 3Health News:Springer and WINFOCUS found new journal 2Health News:Schools Still on Alert for H1N1 Outbreaks 2Health News:For a Healthier Retirement, Work a Little 2Health News:For a Healthier Retirement, Work a Little 3
... the proven electrophoretic transfer apparatus incorporating state-of-the-art plate ... design allows for a very close positioning of ... voltage power source such as a battery charger, ... is exceptionally rapid and exact electrophoretic transfer. ...
... 2 gel holder cassettes, 4 fiber pads, ... buffer chamber, lid with cables, and instructions. ... of Bio-Rad's modular mini electrophoresis system (see ... of mini gels. Its modular electrode assembly ...
... Includes: 2 gel holder ... power cables, fiber pads, blot ... cm). The Trans-Blot transfer cell, ... power supply, performs efficient, high-intensity ...
... running Criterion precast gels and Criterion ... fit for use with the incredible ... Criterion blotter combines excellent blotting efficiency ... system and the ease-of-use of the ...
Medicine Products: